LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Elenco Azioni・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

33.67 4.05

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

32.47

Massimo

34.19

Metriche Chiave
By Trading Economics
Entrata	10M 32M
Vendite	-28M 215M
P/E Media del settore	12.984 49.052
EPS	0.786
Margine di Profitto	15.084
Dipendenti	293
EBITDA	-2.8M 49M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+53.73% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-22M 1.9B
Apertura precedente	29.62
Chiusura precedente	33.67

Notizie sul Sentiment di mercato

By Acuity

34%

66%

90 / 344 Classifica in Healthcare

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 giu 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 giu 2026, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 giu 2026, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 giu 2026, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 giu 2026, 20:51 UTC

Utili

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 20:09 UTC

Discorsi di Mercato

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 giu 2026, 19:36 UTC

Discorsi di Mercato

Cattle Climbs as Crude Oil Falls -- Market Talk

9 giu 2026, 19:32 UTC

Discorsi di Mercato

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 giu 2026, 19:25 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 giu 2026, 19:00 UTC

Discorsi di Mercato

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 giu 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 giu 2026, 18:47 UTC

Discorsi di Mercato

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 giu 2026, 18:37 UTC

Discorsi di Mercato

Canada's Cooling Trade With the U.S. -- Market Talk

9 giu 2026, 18:27 UTC

Discorsi di Mercato

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 giu 2026, 17:35 UTC

Discorsi di Mercato

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 giu 2026, 17:30 UTC

Discorsi di Mercato

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 giu 2026, 16:34 UTC

Discorsi di Mercato

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 giu 2026, 15:28 UTC

Discorsi di Mercato

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 giu 2026, 15:25 UTC

Discorsi di Mercato

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

53.73% in crescita

Previsioni per 12 mesi

Media 49.5 USD 53.73%

Alto 72 USD

Basso 29 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

90 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.